{
  "id": 20483595,
  "title": "GSK’s Nuvalent buyout delivers again as FDA clears Nelkarmi for lung cancer",
  "url": "https://urgent.news/2026/11/17/gsks-nuvalent-buyout-delivers-again-as-fda-clears-nelkarmi-for-lung",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-17T19:50:35.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/gsks-nuvalent-buyout-delivers-again-as-fda-clears-nelkarmi-for-lung-cancer/"
  },
  "original_language": "en",
  "account": null,
  "summary": "GSK has secured a US accelerated approval for its oral lung cancer drug neladalkib, one of two assets at the heart of its $10.6 billion purchase of oncology drugmaker Nuvalent earlier this ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 6,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics",
        "url": "https://urgent.news/2026/11/15/stat-fda-rejects-lung-cancer-treatment-ivonescimab-from-summit",
        "published": "2026-11-15T15:05:15.000Z"
      },
      {
        "outlet": "Financial Times",
        "title": "FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector",
        "url": "https://urgent.news/2026/11/15/fda-rejects-cancer-drug-invented-in-china-in-blow-to-beijings-biotech",
        "published": "2026-11-15T17:07:06.000Z"
      },
      {
        "outlet": "Seeking Alpha News",
        "title": "FDA declines approval of Summit’s lung cancer treatment",
        "url": "https://urgent.news/2026/11/15/fda-declines-approval-of-summits-lung-cancer-treatment",
        "published": "2026-11-15T19:06:39.000Z"
      },
      {
        "outlet": "South China Morning Post",
        "title": "Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback",
        "url": "https://urgent.news/2026/11/16/akeso-shares-plummet-as-chinese-firms-cancer-drug-ivonescimab-faces",
        "published": "2026-11-16T05:00:10.000Z"
      },
      {
        "outlet": "BioPharma Dive",
        "title": "Summit shares fall as FDA rejects closely watched PD-1/VEGF drug",
        "url": "https://urgent.news/2026/11/16/summit-shares-fall-as-fda-rejects-closely-watched-pd-1-vegf-drug",
        "published": "2026-11-16T17:14:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}